A Multicenter, Multinational, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Laquinimod (0.5, 1.0 and 1.5 mg/day) as Treatment in Patients with Huntington's Disease
A study for patients with Huntington's Disease using study drug Laquinimod
Sponsor: Teva Pharmaceuticals
Enrolling: Male and Female Patients
IRB Number: AAAO2317
U.S. Govt. ID: NCT02215616
Contact: Ronda Clouse: 212-305-2387 / rc2682@columbia.edu
Additional Study Information: This study is for patients with Huntington's Disease (HD). The purpose of this clinical study is to find out whether a drug called laquinimod at different doses is safe, and whether it is helpful for people with Huntingtons disease (HD). Laquinimod, the drug being studied in this project, has not been studied in patients with Huntingtons disease. Studies have been conducted using this drug for patients with Multiple Sclerosis, Systemic lupus erythematosus (SLE) and Crohns disease. This study is being conducted to determine if laquinimod helps with the signs and symptoms of Huntingtons disease.
This study is closed
Karen Marder, MD, MPH
Do You Qualify?
Do you have a clinical diagnosis of Huntington's Disease? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Ronda Clouse